Use of NK-1 receptor antogonists for treating substance use diso

Details Use of NK-1 receptor antogonists for treating substance use diso Use of NK-1 receptor antogonists for treating substance use diso

1997-12-01

1999-07-06

Jordan, Kimberly

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

5142378, 514315, 514810, 514811, 514812, 514813, A61K 31535, A61K 31445

Patent

active

059197811

ABSTRACT:
The present invention provides a method for the treatment or prevention of substance use disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

REFERENCES:
patent: 5162339 (1992-11-01), Lowe, III
patent: 5496833 (1996-03-01), Baker et al.
patent: 5538982 (1996-07-01), Hagan et al.
patent: 5612337 (1997-03-01), Baker et al.
patent: 5719147 (1998-02-01), Dorn et al.
patent: 5728695 (1998-03-01), Harrison et al.
Aguiar, M., et al., Physiology & Behavior, 1996, 60(4) 1183-1186.
Barden, N., et al., J. Neurochem., 1983, 41, 834-840.
Brodin, E., et al., Neuropharmacology, 1987, 26(6) 581-590.
Brodin, E., et al., Neuropeptides, 1994, 26, 253-260.
Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885-891.
Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87.
Elliott, P.J., Exp. Brain Res. UK, 1988, 73, 354-356.
F-D-C Reports--Prescription Pharmaceuticals and Biotechnology, Dec. 8, 1997, 59 (49), 10.
File, S.E., Pharm. Biochem. Behavior, 1997, 58, 3, 747-752.
Kramer, et al., Science, 1998, 281, 1640-1645.
Lowe, J., et al., Drug News Perspect, 1992, 5 (4), 223.
Malek-Ahmadi, Neuroscience and Behavioral Reviews, 1992, 16, 365-359.
Rimon, R., et al., Biological Psychiatry, 1984, 19(4), 509-516.
Roccon, et al., Pharmacological Research, 1995, 31, 191.
Shaikh, M., et al., Brain Research, 1993, 625, 283-294.
Shirayama, Y., et al., Brain Research, 1996, 739, 70-78.
Siegel, R., et al., Neurochem. Int., 1984, 6(6), 783-789.
Siegel, A., et al., Aggressive Behavior, 1995, 21, 49-62.
Teixeira, R., et al., European J. Pharm., 1996, 311, 7-14.
Vassout, et al., Neuropeptides, 1994, 26 (Suppl. 1), 38.
Wahlestedt Science, 1998, 281, 1624-1625.
Wall Street Journal, Aug. 13, 1998, B1, Col. 2.
CA 120:69382, McLean et al., 1993.

Affiliated with

Also associated with

Rating

Use of NK-1 receptor antogonists for treating substance use diso does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of NK-1 receptor antogonists for treating substance use diso, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of NK-1 receptor antogonists for treating substance use diso will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-899166